1Pan HW, Ou YH, Peng SY, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma[ J]. Cancer,2003,98( 1 ) :119-127.
2Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies [ J ]. Clin Cancer Res ,2004 ,10 ( 1 ) : 184 -190.
3Schorge JO, Drake RD, Lee H, et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer[ J]. Clin Cancer Res, 2004,10(10) :3474- 3478.
4Singhal H, Bautista DS, Tonkin KS, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival[J]. Clin Cancer Res, 1997,3 (4) :605- 611.
5Le QT, Sutphin PD, Raychaudhuri S,et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas[J]. Clin Cancer Res, 2003,9 (1) :59-67.
6Kim J H, Skates SJ, Uede T,et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer [ J ]. JAMA, 2002,287 (13) : 1671-1679.
7Brakora KA, Lee H, Yusuf R, et al. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer [J]. Gynecol Oncol, 2004,93 (2) :361-536.
